Impact of imatinib interruption and duration of prior hydroxyurea on the treatment outcome in patients with chronic myeloid leukemia: Single institution experience
Background: Optimal response requires that patients should be maintained on the drug continuously. Objectives: To evaluate the influence of imatinib interruption and prior hydroxyurea use on the outcome of patients with chronic myeloid leukemia. Materials and methods: Between January 2010 and Novemb...
Main Authors: | Wael Abdelgawad Edesa, Raafat Ragaey Abdel-malek |
---|---|
Format: | Article |
Language: | English |
Published: |
SpringerOpen
2015-06-01
|
Series: | Journal of the Egyptian National Cancer Institute |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1110036215000291 |
Similar Items
-
Comparative study for the efficacy, safety and quality of life in patients of chronic myeloid leukemia treated with Imatinib or Hydroxyurea
by: Parveen Jain, et al.
Published: (2013-01-01) -
Upfront Combined Hydroxyurea and Imatinib versus Imatinib Monotherapy in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: A Randomized Controlled Trial
by: Rituparna Chetia, et al. -
IMATINIB IN CHRONIC MYELOID LEUKEMIA: AN OVERVIEW
by: Tomasz Sacha
Published: (2013-12-01) -
Curcumin Decreases Viability and Inhibits Proliferation of Imatinib-Sensitive and Imatinib-Resistant Chronic Myeloid Leukemia Cell Lines
by: Esma Bilajac, et al.
Published: (2022-12-01) -
OUR EXPERIENCE WITH TREATMENT OF CHRONIC MYELOID LEUKEMIA WITH IMATINIB MESYLATE
by: Mojca Modic, et al.
Published: (2004-12-01)